Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Two types amyloid infiltration of the heart: diagnostic challenges and therapeutic strategies

dc.contributor.authorRamos Polo, Raúl
dc.contributor.authorJiménez Marrero, Santiago
dc.contributor.authorMorillas, Herminio
dc.contributor.authorPons Riverola, Alexandra
dc.contributor.authorGaray, Alberto
dc.contributor.authorCarro, Itziar
dc.contributor.authorGràcia, Laura Maria
dc.contributor.authorBaixeras, Núria
dc.contributor.authorSánchez Vega, Jesús
dc.contributor.authorMoliner, Pedro
dc.date.accessioned2026-05-05T13:22:47Z
dc.date.available2026-05-05T13:22:47Z
dc.date.issued2026-01-27
dc.date.updated2026-04-21T15:06:59Z
dc.description.abstractBackground Amyloidosis is characterized by extracellular deposition of insoluble fibrils, with light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) being the most common cardiac subtypes. Early detection and multimodal diagnostic strategies are critical for effective treatment. Case summary A 83-year-old woman presented with pseudoinfarction electrocardiogram pattern. Investigations revealed concentric left ventricular hypertrophy and elevated NTproBNP. Multimodality imaging approach confirmed cardiac amyloidosis, both with a monoclonal IgG Lambda component and Perugini grade 3 uptake. Endomyocardial biopsy (EMB) identified dual amyloid infiltration with Lambda light chains and transthyretin. Both hematological and heart failure treatment resulted in clinical improvement. Discussion Two different types of cardiac amyloidosis can coexist on the same patient. This case underscores the importance of advanced diagnostic techniques, such as 18F-florbetaben PET-CT. Histological amyloid subtype identification is key when tests are inconclusive. Take home messages Multimodality imaging and histological confirmation are key for cardiac amyloidosis diagnosis. Early initiation of disease-modifier therapies can significantly impact on disease progression.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid41593755
dc.identifier.urihttps://hdl.handle.net/2445/229316
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s40959-025-00430-6
dc.relation.ispartofCardio-Oncology, 2026, vol. 12, num. 1
dc.relation.urihttps://doi.org/10.1186/s40959-025-00430-6
dc.rightscc by-nc-nd (c) Ramos Polo, Raúl et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.titleTwo types amyloid infiltration of the heart: diagnostic challenges and therapeutic strategies
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s40959-025-00430-6.pdf
Mida:
2.22 MB
Format:
Adobe Portable Document Format